Fintech PR
Manulife Named to 2024 Corporate Knights Global 100
Ranking fourth within the Insurance industry, Manulife recognized for performance in sustainable revenues and investments
DAVOS, Switzerland, Jan. 17, 2024 /PRNewswire/ — Manulife (TSX: MFC) has been named to the 2024 Corporate Knights Global 100 rankings as one of the world’s most sustainable companies. Now in its 20th year, the Global 100 quantitatively compares and ranks how the world’s largest publicly traded companies embrace sustainability as part of its strategy, equally emphasizing the impact of a company’s operations along with its core products and services on people and the planet. The ranking is based on a rigorous assessment of 6,720 companies with more than US$1 billion in annual gross revenues.
“When we first introduced our Impact Agenda, we were excited to have a framework in place to help us continue to build a business capable of meeting the evolving needs of our customers, our communities, and our environment,” said Roy Gori, Manulife’s President and CEO. “As the world continues to experience geopolitical, environmental, and economic uncertainty, it’s important that the contributions our products and services make to the global economy are guided by this vision. This honour is a testament to the work our teams do to make decisions easier and lives better for our more than 34 million customers.”
Manulife’s performance in the Global 100 assessment was driven largely through revenues earned from sustainable sources. Through its behavioural insurance program, Manulife continues to expand the availability of products and services that empower sustained health and well-being such as Vitality and ManulifeMOVE, which provide eligible customers access to leading innovations, like GRAIL’s Galleri® multi-cancer early detection test. Through its investment management arm, the organization has a robust sustainable investment program through portfolio ESG integration across its public and private market investments and is the world’s largest manager of natural capital with nearly $15 billion in assets under management in timberland and agriculture combined.
Corporate Knights also recognized Manulife’s strong long-term focus on diversity at the Board and executive management levels, and in connecting sustainability to compensation and performance. For 2022, 64% of the independent directors on Manulife’s Board self-identified as women1 and 27% of the independent directors on the Board self-identified as members of a visible minority2. Manulife’s full scorecard is available on the Corporate Knights website.
“As a health and wealth company, we know how important it is to accelerate a sustainable future and drive inclusive economic opportunity,” said Sarah Chapman, Manulife’s Global Chief Sustainability Officer. “Through our Impact Agenda, we are continuing to address urgent global needs that matter most to our colleagues, our clients, and the communities we serve. To be named to the Global 100 is an honour, and we remain committed to harnessing our unique strengths and the diversity of our business to deliver benefits for our business, our people and our planet.”
In addition to being named to this year’s Global 100, Manulife has also been recognized by Corporate Knights as one of Canada’s Top 50 Companies for the last three years. In 2023, Manulife was ranked within approximately the top 2 per cent of its Financials and Insurance Global Industry Classification Standard (GICS) sector and industry peer groups, respectively. Manulife’s full scorecard is available on the Corporate Knights website.
More recently, Manulife was one of only eight insurers to be named to this year’s Dow Jones Sustainability North America Index, underscoring Manulife’s leading sustainable business practices and its proven ability to deliver long-term shareholder value.
Visit Manulife.com/sustainability to learn more about the firm’s Impact Agenda and to read its 2023 Environmental, Social, and Governance (ESG) Report.
|
______________________________________ |
|
|
1 |
Data as of February 28, 2023. |
|
2 |
As defined by the Employment Equity Act (Canada). Data as of February 28, 2023 |
Manulife Financial Corporation is a leading international financial services provider, helping people make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we provide financial advice and insurance, operating as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States. Through Manulife Investment Management, the global brand for our Global Wealth and Asset Management segment, we serve individuals, institutions, and retirement plan members worldwide. At the end of 2022, we had more than 40,000 employees, over 116,000 agents, and thousands of distribution partners, serving over 34 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges and under ‘945’ in Hong Kong.
View original content:https://www.prnewswire.co.uk/news-releases/manulife-named-to-2024-corporate-knights-global-100-302036637.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News5 days ago
AI-powered Panax raises $15m to reshape cash flow management
-
Latest News5 days ago
Yili’s 2023 Revenue Reaches 126.2 Billion Yuan, Leading Global Dairy Industry towards Healthy and Sustainable Development
-
Latest News5 days ago
“Grand Huangshan” Debuts at the 2024 World Brand Moganshan Conference
-
Latest News5 days ago
Egypt’s Swypex launches an all-in-one fintech platform after $4m seed round
-
Latest News5 days ago
Sweden’s Mitigram names Pedram Tadayon as new CEO
-
Latest News5 days ago
South African fintech Lesaka snaps up Adumo in $86m deal
-
Latest News5 days ago
India has remained a steady ship in choppy waters says DSP Asset Managers
-
Latest News4 days ago
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase